Asset Details
Do you wish to reserve the book?
Current diagnosis and treatment of visceral leishmaniasis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Current diagnosis and treatment of visceral leishmaniasis
Do you wish to request the book?
Current diagnosis and treatment of visceral leishmaniasis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Current diagnosis and treatment of visceral leishmaniasis
2010
Overview
Human visceral leishmaniasis (VL), a potentially fatal disease, is most prevalent in the Indian subcontinent, East Africa and South America. Definite diagnosis and effective treatment are the primary needs for the control of VL. Diagnosis of VL has typically relied on microscopic examination of bone marrow/splenic aspirate, but serology and molecular methods are now better alternatives. The conventional drugs for treatment of VL have limitations including unresponsiveness, relapse, specific toxicities and parenteral administration lasting for long durations. Moreover, they are less effective in HIV-VL-coinfected patients. Registration of miltefosine and paromomycin, and preferential pricing of AmBisome has offered more choices for monotherapy and combination therapy for VL. Combination therapy will increase treatment efficacy and prevent the development of resistance. In addition, active case finding and vector control strategies will also have a positive impact in the control of VL. This article critically addresses the currently available diagnostic and treatment regimens for the control of VL.
Publisher
Taylor & Francis,Expert Reviews Ltd,Informa Healthcare
Subject
/ Amphotericin B - therapeutic use
/ Animals
/ Antigens, Protozoan - genetics
/ Antigens, Protozoan - immunology
/ Antiprotozoal Agents - therapeutic use
/ Enzyme-Linked Immunosorbent Assay
/ Human immunodeficiency virus
/ Humans
/ Leishmaniasis, Visceral - diagnosis
/ Leishmaniasis, Visceral - drug therapy
/ Leishmaniasis, Visceral - parasitology
/ Phosphorylcholine - analogs & derivatives
/ Phosphorylcholine - therapeutic use
/ Protozoan Proteins - genetics
/ Protozoan Proteins - immunology
/ Recombinant Proteins - genetics
